Clene Osingo per osake

Mitä Clene tekee? Clene Inc is a clinical-stage biopharmaceutical company based in Salt Lake City, Utah, operating within the health care sector and specifically in the biotechnology industry. The company went public via an IPO on August 27, 2018, and currently employs 75 full-time staff. Clene focuses on developing therapeutics for neurodegenerative diseases, with its primary drug candidate being CNM-Au8, an oral suspension of gold nanocrystals. The company's research targets energetic failure, an underlying factor in many neurological conditions, aiming to restore neuronal health and function by enhancing energy production and utilization. CNM-Au8 works through catalytically active nanocrystals that support cellular energy processes, promoting neuroprotection and remyelination by improving resilience to disease-related stressors. The company also has other product candidates, including CNM-ZnAg, a spectrum antiviral and antibacterial agent composed of zinc and silver ions, and CNM-AgZn17, a gel polymer suspension of zinc and silver designed for treating infectious diseases and supporting wound healing. Clene's website is https://clene.com/ and it is listed under the ticker CLNN with ISIN US1856342019. The company remains in the clinical development phase, focusing on advancing its pipeline of treatments for neurological and infectious conditions. Clene on yksi Eurpooliin suosituimmista yhtiöistä.